For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 16,360,725 | |||
| General and administrative | 12,344,976 | |||
| Loss from operations | -28,705,701 | |||
| Interest income | 249 | |||
| Non-operating expenses | 1,472,995 | |||
| Change in fair value of warrant liability | -1,424,603 | |||
| Total other income/expense | -48,143 | |||
| Net loss | -28,753,844 | |||
| Net loss available to common shareholders | -28,753,844 | |||
| Basic EPS | -0.98 | |||
| Diluted EPS | -0.98 | |||
| Diluted Average Shares | 29,253,292 | |||
OS Therapies Inc (OSTX)
OS Therapies Inc (OSTX)